Lilly ups bid for ICOS, analysts shrug off negative story

12/18/2006 | Forbes

Eli Lilly increased its bid for ICOS Corp. from $2.1 billion to $2.3 billion, and Lilly says the boards of both companies have unanimously approved the revised merger. Analysts seemed unfazed by a negative newspaper report of Lilly's marketing of its Zyprexa drug, with one saying the allegations in the story "are fairly widely known."

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN